On Wednesday, Following Stocks were among the “Top 50 Losers” of U.S. Stock Market: RSP Permian Inc (NYSE:RSPP), Emerald Oil Inc (NYSEMKT:EOX), USG Corporation (NYSE:USG), Juno Therapeutics Inc (NASDAQ:JUNO)

RSP Permian Inc (NYSE:RSPP), with shares declined -4.91%, closed at $25.74.

Emerald Oil Inc (NYSEMKT:EOX), with shares dropped -4.81%, settled at $0.860.

USG Corporation (NYSE:USG), with shares dipped -4.73%, and closed at $25.39.

Juno Therapeutics Inc (NASDAQ:JUNO), plummeted -4.59%, and closed at $50.93.

Latest NEWS regarding these Stocks are depicted underneath:

RSP Permian, Inc. (NYSE:RSPP)

On Tuesday, RSP Permian, Inc. (RSPP), declared that it has priced an underwritten public offering of 5,000,000 shares of its ordinary stock by the Corporation and 4,000,000 shares of its ordinary stock by certain of the Corporation’s stockholders at $25.80 per share. Total gross proceeds (before the underwriter’s discounts and commissions and estimated offering expenses) will be about $129.0 million to the Corporation and about $103.2 million to the selling stockholders. The Corporation and the selling stockholders have granted the underwriter a 30-day option to purchase up to 750,000 and 600,000 additional shares of the Corporation’s ordinary stock, respectively. The offering is predictable to close on March 23, 2015, subject to customary closing conditions.

The Corporation intends to use the net proceeds from this offering, counting the proceeds from any exercise of the option to purchase additional shares of ordinary stock, to repay all outstanding borrowings under its revolving credit facility and the balance for general corporate purposes, which may comprise funding its drilling and development program and future attainments. The Corporation will not receive any of the proceeds from the sale of the shares of ordinary stock by the selling stockholders.

Barclays Capital Inc. is acting as the sole underwriter of the offering.

RSP Permian, Inc., an independent oil and natural gas corporation, engages in the attainment, exploration, development, and production of unconventional oil and associated liquids-rich natural gas reserves in the Permian Basin of West Texas.

Emerald Oil, Inc. (NYSEMKT:EOX)

Emerald Oil, Inc. (EOX), declared financial and operational results for the quarter and year ended December 31, 2014, on March 10.

For 2014, Emerald’s total production volumes on a BOE basis raised 110% as contrast to 2013. Production raised due to the addition of 24.19 net productive operated Bakken/Three Forks wells in 2014. During 2014, Emerald realized an $84.01 average price per Bbl of oil (counting settled derivatives) contrast to an $87.16 average price per Bbl of oil during 2013.

As of December 31, 2014, Emerald had total proved reserves of about 26.3 MMBoe, all of which were located in the Williston Basin. Emerald’s proved reserves raised about 99% during 2014 primarily as a result of our successful operated well program. The proved reserves total had a pre-tax PV10% value of $535.1 million.

Proceeds from sales of oil and natural gas for the quarter ended December 31, 2014 were $22.1 million contrast to $17.9 million for the same period in 2013. Proceeds, not considering the effect of derivatives, for the year ended December 31, 2014 were $101.2 million contrast to $54.0 million for the same period in 2013. The raise is primarily due to higher production as a result of the Corporation’s well completions and its attainment of certain properties throughout its core operating areas.

Adjusted EBITDA was $15.0 million for the quarter ended December 31, 2014, as contrast to $5.0 million for the same period in 2013. For the year ended December 31, 2014, Adjusted EBITDA was $56.8 million, as contrast to $20.2 million for 2013. Adjusted Net Revenue was $2.0 million for the quarter ended December 31, 2014 as contrast to a loss of $1.1 million in the same period in 2013. For the year ended December 31, 2014, Adjusted Net Revenue was $16.8 million, as contrast to $2.4 million for 2013. Adjusted EBITDA and Adjusted Net Revenue are non-GAAP financial measures.

Emerald Oil, Inc. operates as an independent oil and natural gas exploration and production corporation in the United States. The corporation designs, drills, and operates oil and natural gas wells. It primarily focuses on acquiring acreage and developing oil and natural gas wells in the Williston Basin located in North Dakota and Montana.

USG Corporation (NYSE:USG)

Formerly on February 24, USG Corporation (USG), declared the settlement of the formerly confirmed cash tender offer for any and all of its outstanding 8.375% Senior Notes due 2018. The Tender Offer expired at 5:00 p.m., New York City time, on February 23, 2015. At the Expiration Time, valid tenders had been received with respect to about $126 million of the $350 million aggregate principal amount of the 2018 Notes outstanding.

USG has accepted for payment all 2018 Notes validly tendered preceding to the Expiration Time. On February 24, 2015, such tendering holders received the purchase price in the amount of $1,046.38 for each $1,000 principal amount of 2018 Notes tendered, plus accrued and unpaid interest to, but not counting, the date hereof. In accordance with the indenture governing the 2018 Notes, USG has issued an irrevocable notice of redemption with respect to all outstanding 2018 Notes that were not tendered in the Tender Offer. The redemption date is March 26, 2015.

USG also declared the settlement of its formerly declared private offering of $350 million aggregate principal amount of its 5.50% Senior Notes due 2025 on February 24, 2015. The New Notes matured on March 1, 2025.

USG Corporation, through its auxiliaries, operates as a manufacturer and distributor of building materials worldwide. Its Gypsum segment provides gypsum and related products that are used to construct walls, ceilings, roofs, and floors of residential, commercial, and institutional buildings, in addition to in various industrial applications.

Juno Therapeutics Inc. (NASDAQ:JUNO)

On Wednesday, Juno Therapeutics Inc. (JUNO), a biopharmaceutical corporation focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, stated business highlights and financial results for the fourth quarter and year ended December 31, 2014.

Fourth Quarter and 2014 Financial Results:

Cash, cash equivalents, and marketable securities as of December 31, 2014 were $474.1 million contrast to $36.0 million as of December 31, 2013. The raise was primarily due to net proceeds from convertible preferred stock issuances of $245.9 million and net proceeds from Juno’s initial public offering of $281.4 million, offset by a cash burn of $89.2 million.

Cash burn of $89.2 million in 2014 comprised primarily of cash used in operations of $82.5 million, investment in the preferred stock of a planned supplier of $3.5 million, and purchases of property and equipment of $2.9 million.

Research and development expenses, inclusive of non-cash expenses, computed in accordance with GAAP, were $182.1 million for the fourth quarter of 2014 and $204.5 million for the year ended December 31, 2014. Comprised of in R&D costs are expenses related to the change in estimated value and accrual period for Juno’s potential success payments to the Fred Hutchinson Cancer Research Center (FHCRC) and Memorial Sloan Kettering Cancer Center (MSK), upfront cash and stock payments to attain technology related to JCAR018, and costs to expand Juno’s overall research and development capabilities and advance programs at Juno’s founding institutions.

General and administrative expenses, inclusive of non-cash expenses, computed in accordance with GAAP, were $6.1 million for the fourth quarter of 2014 and $19.5 million for the year ended December 31, 2014, comprising of personnel costs, counting non-cash stock-based compensation expense, and patent and corporate legal fees.

Litigation expenses were $3.7 million for the fourth quarter of 2014 and $8.7 million for the year ended December 31, 2014. Litigation expense was comprised of costs Juno incurred with respect to Trustees of the University of Pennsylvania v. St. Jude Children’s Research Hospital, Civil Action No. 2:13-cv-01502-SD (E.D. Penn.), in addition to expenses Juno is required to reimburse to St. Jude Children’s Research Hospital with respect to such litigation.

Net loss attributable to ordinary stockholders for the fourth quarter of 2014 was $191.9 million, or $13.68 per share. Net loss attributable to ordinary stockholders for the year ended December 31, 2014 was $310.9 million, or $36.82 per share.

Juno Therapeutics, Inc., a biopharmaceutical corporation, engages in developing cell-based cancer immunotherapies. The corporation develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.